Navigation Links
Downgraded Tier Positions and Step Therapy Restrictions Have Stalled Exforge's and Tekturna's Growth in The Hypertension Drug Market
Date:12/10/2008

MCO Pharmacy Directors Favor Individual, Generic Drugs Versus Newer Single-Pill Fixed Combination Brands, According to a New Report from HealthLeaders-InterStudy

NASHVILLE, Tenn., Dec. 10 /PRNewswire/ -- HealthLeaders-InterStudy, a leading provider of managed care market intelligence, finds that although Novartis' Exforge and Tekturna have slowly penetrated tier 2 levels of managed care organization (MCO) formularies over the last 12 months, their progress has stalled. Tekturna has stumbled from having 5.1 percent of U.S. patients accessing the drug at tier 2 in August 2008 to having only 3.9 percent of all patients with access at that same level in November 2008. According to the new Formulary Forum report entitled Formulary Advantages in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations, more surveyed MCO pharmacy directors indicate that they have downgraded Exforge's and Tekturna's tier position and/or added step therapy restrictions than indicated they had improved tier positioning of the drugs.

"The future reimbursement outlook for repackaging of individual hypertension agents is not that promising," according to Jason Labonte, Ph.D., vice president at HealthLeaders-InterStudy. "Forty-four to 67 percent of survey respondents favor use of individual (and often generic) drugs versus the newer single-pill, fixed-combination brands like Exforge and Daiichi Sankyo's Azor."

About Formulary Advantages in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations

The new Formulary Forum report is based on a survey of 50 pharmacy directors who control national, regional and state-level MCOs. Answers were segmented by type of plan to illustrate variances in strategy by size of plan. The easy-to-use PowerPoint format allows users to cut-and-paste graphs and data into their own presentations.

About Formulary Forum

Formulary Forum is the first and only source for identifying the trends in formulary positioning of competing agents, understanding why those trends were taking place and predicting what changes lay ahead for brand positioning in the face of both patent expiries and new drug launches. The new report series from HealthLeaders-InterStudy combines historical formulary data from Fingertip Formulary, which maintains the highest quality and most comprehensive, integrated database of formulary information in the United States, with a robust survey of 50 MCO pharmacy directors. The pharmacy directors responses reveal what events triggered movement of key brands within their formulary for a specific disease as well as what moves they expect to make in formulary structure as new brands enter the market.

About Fingertip Formulary

Fingertip Formulary (www.FingertipFormulary.com) offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others, in the United States. Fingertip Formulary is a Decision Resources, Inc. company.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Lisa Osgood                                 Elizabeth Marshall
    HealthLeaders-InterStudy                    Decision Resources, Inc.
    781-296-2606                                781-296-2563
    losgood@hl-isy.com                          emarshall@dresources.com


'/>"/>
SOURCE HealthLeaders-InterStudy
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions
2. More Than 1,600 Positions to be Filled at PharmaDiversity Job Board's eJobFair in September
3. Siemens Healthcare Executives Recognized With New Industry Leadership Positions
4. Essilor Strengthens its Positions in Italy - Three New Acquisitions in the United States
5. Debate Will Feature Clinton-Obama Positions on Health Care Followed by Straw Poll
6. New therapy prevents dangerous side effect for lymphoma patients
7. Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
8. Statin Use Doesnt Inhibit Lymphoma Drug Therapy
9. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
10. 33rd Annual Hutch Holiday Gala Raises Millions for Cancer Immunotherapy Research
11. Lenalidomide safe as single therapy for elderly CLL patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... The Association of Healthcare and ... hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will provide ... and value analysis professionals have a ‘seat at the table’ with clinical committees ...
(Date:3/27/2017)... , ... March 27, 2017 , ... According to the ... cancer, including all stages, is more than 95%. Once the cancer spreads to other ... than 30%. To find out how to avoid this latter group, tune in to ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium ... methods are complicated and require expert user knowledge. In a live webinar on ... to the simplified, yet highly accurate, determination of sodium. , It has long ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending LLC announced ... litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ ... to announce that we have now reached a settlement agreement regarding the ongoing ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 ... has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription opioids ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... --  Genprex, Inc. , a privately held, clinical-stage biopharmaceutical company developing ... Company,s Chief Operating Officer, is scheduled to present a corporate overview ... Annual Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 at ... ... Annual Future Leaders in Biotech Industry – Friday, April 7, 2017 ...
(Date:3/27/2017)... -- Invivotek, LLC, a Genesis Biotechnology Group ® ... contract research organization (CRO), announced the completion of the ... research facility in Hamilton, New Jersey ... source to reduce costs and lessen the CRO facility,s ... Farm follows Invivotek,s recent expansion from a 19,712 square ...
(Date:3/24/2017)... Oregon and PUNE, India , March 24, 2017 /PRNewswire/ ... 2015, and is estimated to reach $2,614 million by 2022, Globally, registering a CAGR ... to generate the highest revenue, and is projected to dominate the market during the ... ... Allied Market Research Logo ...
Breaking Medicine Technology: